ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Immunologic Basis for Immunocloaking.

L. Brasile,1 K. Kizjakina,1 N. Henry,1 B. Stubenitsky.2

1BREONICS Inc., Watervliet, NY
2Plastic Surgery, University of Utrecht, Utrecht, Netherlands.

Meeting: 2016 American Transplant Congress

Abstract number: A21

Keywords: Allorecognition, Antigen presentation, Kidney transplantation, Rejection

Session Information

Date: Saturday, June 11, 2016

Session Name: Poster Session A: B cells & AMR, Alloreactivity, Immune Regulation & Regulatory T Cells, T Cell Biology and Alloreactivity, Immunesuppression

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Halls C&D

Related Abstracts
  • Clinical Impact of Pre-Transplant Serum 25-Hydroxyvitamin D Levels on the Post-Transplant Immunologic and Non-Immunologic Outcomes in Kidney Transplant Recipients.
  • ASC-Deficient Dendritic Cells Exhibit Activation Defects and a Reduced Ability to Stimulate Allogeneic T Cells.

A novel organ-specific immunomodifying therapy referred to as immunocloaking (IC) provides protection from early allograft rejection without immunosuppressive drugs. The IC binds to the surfaces of the vasculature within kidneys, interrupting the interface between donor endothelium (VEC) and recipient immune cells; without adversely affecting renal function. The result is a newly engineered non-immunogenic apical surface. We now report the underlying protective mechanisms involved with IC.

Methods: The IC membrane was applied to confluent human VEC. The immunologic testing included: effect of IC on antigen presentation, T cell activation & proliferation and diapedsis using standard methodology with flow cytometry, Luminex screening, proliferation assays and chemotactic-driven diapedesis. Testing used responding mononuclear cells (MNC) stimulated by confluent allogeneic VEC without (negative control) and with IC (test). Transendothelial migration involved VEC grown on filters in Transwell™ plates. MNC (1X104) were added to the upper chambers and chemoattractant SDF-1, a potent chemotactic factor for lymphocytes, was added to the lower chambers to form chemokine gradients.

Results: The IC membrane prevents antigen presentation and early T cell activation, eliminating T cell proliferation. The results from these studies demonstrate VEC strongly stimulated MNC. IC VEC inhibited responses by >99% . Transmigration: In negative controls without SDF-1 few MNC migrated through VEC layers into the lower chambers. In positive controls >65% of the cells migrated through the VEC into the lower chambers containing the SDF-1. In IC/VEC monolayers, the MNC migration into lower chambers with the SDF-1 was inhibited by a mean of 86.7%.

Conclusions: We previously demonstrated that IC prevents renal allograft rejection with a mean of 30 days with no immunosuppression. How the IC prevented rejection was previously unknown. We now show that IC temporarily prevents alloresponses. Significantly, IC prevents chemokine-stimulated transmigration. Eliminating the need for nephrotoxic drugs during the early posttransplant period could help to ameliorate the severity of delayed graft function.

CITATION INFORMATION: Brasile L, Kizjakina K, Henry N, Stubenitsky B. Immunologic Basis for Immunocloaking. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Brasile L, Kizjakina K, Henry N, Stubenitsky B. Immunologic Basis for Immunocloaking. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/immunologic-basis-for-immunocloaking/. Accessed March 2, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.